ZP1848, a Novel GLP-2 Agonist, Provides a Wide Window of Therapeutic Efficacy in the Experimental Crohn's Disease Model

animal weight loss, as well as colonic TNF-α and vimentin expression. Conclusions: TRF did not prevent intestinal fibrosis in an optimized rat model. However, treatment with TRF had anti-inflammatory effects, decreasing some of the clinical hallmarks of TNBS-induced colitis. We therefore can't rule out the possibility that treatment with TRF for longer periods of time might improve intestinal fibrosis.